April 20, 2005
EntreMed Presents Preclinical Data for Second Generation 2ME2 CompoundsApril 20, 2005
EntreMed and Collaborators Present Data for 2ME2 Mechanisms of Action at AACRApril 19, 2005
EntreMed Presents Preclinical Data for Novel PAR-2 Antagonist to Treat Cancer and Inflammatory DiseaApril 14, 2005
EntreMed Granted FDA Orphan Drug Status for Panzem® (2ME2) in Ovarian CancerApril 11, 2005
Disease Modifying Activity of 2ME2 in Rheumatoid Arthritis Validated in Second Preclinical StudyApril 05, 2005
EntreMed Presents Preclinical Data for 2ME2 in Rheumatoid ArthritisApril 01, 2005
EntreMed Announces Celgene InvestmentMarch 25, 2005
EntreMed and Celgene Enter Into Licensing Agreement for the Development of Tubulin Inhibitor CancerMarch 09, 2005
EntreMed Reports Fourth Quarter and Year-End 2004 Financial ResultsMarch 08, 2005
EntreMed to Present at SG Cowen Health Care ConferenceFebruary 23, 2005
EntreMed Presents Progress on PAR-2 Program in Oncology and InflammationFebruary 18, 2005
EntreMed to Participate in Anti-Angiogenesis Panel at BIO CEO ConferenceFebruary 17, 2005
EntreMed Appoints Pharmaceutical Executive to Senior Management TeamFebruary 14, 2005
EntreMed Reports on Anticancer Progress at Angiogenesis SymposiumJanuary 19, 2005
Report Demonstrates Activity of 2ME2 With Paclitaxel in Head and Neck CarcinomaJanuary 05, 2005
EntreMed Commences Clinical Trials of Panzem(R) NCD in Patients With Advanced Cancer
